| INTRODUCTION
An estimated three million individuals are chronically infected with hepatitis C virus (HCV) in the United States.
1 HCV infection leads to the development of liver cirrhosis in one-fifth of patients within 20-30 years and is a leading cause of liver transplantation, hepatocellular carcinoma and death. 2 Patients who develop decompensated liver disease, characterized by ascites, reduction in albumin, prolongation of international normalized ratio, hepatic encephalopathy and/ or spontaneous bacterial peritonitis, have decreased survival rates vs patients with compensated cirrhosis.
3,4
Treating patients with advanced liver disease has been historically associated with limited success. 5 In addition to the intrinsic fragility of these patients, decompensated liver disease may result in impaired hepatic metabolism, affecting the plasma concentrations of HCV direct-acting antiviral agents (DAAs). 6 Therefore, treatment options must be carefully considered. 6 Furthermore, it has been reported that some DAAs may cause liver injury in patients with underlying cirrhosis. 7 Until 2011, the standard of care for chronic HCV infection was peginterferon and ribavirin. However, this regimen is contraindicated in patients with decompensated cirrhosis due to poor tolerability. Since 2011, DAAs have become available, leading to the introduction of better-tolerated, interferon-/ribavirin-free, all-oral regimens. Current guidelines for patients with decompensated cirrhosis recommend the fixed-dose combination of sofosbuvir, ledipasvir and ribavirin for 12 weeks (for genotypes [GTs] 1, 4, 5 and 6), 8, 9 for which sustained virologic response 12 weeks after the end of treatment (SVR12) rates of 86%-89% and 85%-87% has been reported for the SOLAR-1 and SOLAR-2 studies, respectively, in nontransplant patients with Child-Pugh (CP) class B or C cirrhosis. 10, 11 The combination of sofosbuvir, daclatasvir and ribavirin for 12 weeks (all GTs) is also recommended, 9 and SVR12 rates of 82% have been reported with this regimen in the ALLY-1 study in GT1-infected patients with CP A, B or C. 12 Furthermore, a real-world study conducted in the United
Kingdom resulted in SVR12 rates of 88% and 91% with sofosbuvir, daclatasvir and ribavirin in GT1-infected patients with decompensated cirrhosis. 13 Simeprevir, sofosbuvir and daclatasvir are among the DAAs approved for the treatment of chronic HCV infection. Simeprevir is an HCV NS3/4A protease inhibitor with antiviral activity against GTs 1, 2, 4, 5 and 6; sofosbuvir is a pangenotypic nucleotide HCV NS5B polymerase inhibitor; and daclatasvir is a pangenotypic HCV NS5A replication complex inhibitor. Simeprevir has been evaluated in combination with sofosbuvir and/or daclatasvir in patients with compensated liver disease as part of an interferon-free regimen with/without ribavirin, leading to SVR12 rates of 69%-93%. [14] [15] [16] [17] In the SODAPI study, which evaluated three weeks of simeprevir in combination with sofosbuvir and daclatasvir in Chinese HCV GT1b-infected patients without cirrhosis, an SVR12 rate of 100% was reported.
18
The Phase II IMPACT study assessed for the first time the combination of simeprevir, sofosbuvir and daclatasvir (DAAs with different mechanisms of action and metabolic pathways, as well as non-overlapping resistance profiles) for 12 weeks in HCV GT1-or 4-infected, treatment-naïve or treatment-experienced patients with portal hypertension or decompensated liver disease. lower limit of quantification=limit of detection=15 IU/mL) (Appendix S1).
| METHODS

| Patients and study design
Sequencing of the HCV NS3/4A, NS5A and NS5B regions was performed pretreatment in all patients to identify pre-existing sequence polymorphisms (Appendix S1).
Liver disease status was monitored through the assessment of CP, model for end-stage liver disease (MELD), FibroTest (BioPredictive, Paris, France) and FibroScan ® scores which were assessed at either screening or baseline, and during follow-up. Change over time in CP and MELD scores from baseline to follow-up were recorded.
Pharmacokinetic (PK) data were collected as described in Appendix S1. Adverse events (AEs) were monitored throughout the treatment period up to week 4 of follow-up (Appendix S1).
| Outcomes
The primary efficacy endpoint was SVR12 (HCV RNA <15 IU/mL detectable or undetectable 12 weeks after the actual EOT) in the intent-to-treat (ITT) population (all patients who received at least one dose of the study drugs).
Key secondary endpoints included the following: SVR rate 4 weeks after EOT; SVR rate 24 weeks after EOT (SVR24); on-treatment virologic response (HCV RNA <15 IU/mL detectable or undetectable at all time points); on-treatment failure including viral breakthrough (confirmed >1.0 log 10 increase in HCV RNA from nadir or confirmed HCV RNA >100 IU/ mL in patients who had previously achieved HCV RNA <15 IU/mL ontreatment); viral relapse (patients not achieving SVR12, with undetectable HCV RNA at EOT and confirmed HCV RNA ≥15 IU/mL during follow-up); changes from baseline in the HCV NS3/4A, NS5A and NS5B sequences in patients not achieving SVR12; PK parameters for simeprevir, daclatasvir, sofosbuvir and GS-331007; and safety and tolerability.
Exploratory endpoints included the effect of treatment on liver disease status.
| Statistics
As this was an exploratory study, no formal sample size calculation was performed. A sample size of 20 patients per panel was determined based on considerations of estimating the SVR rate and the exact 95%, two-sided confidence intervals (CIs) with sufficient precision (Appendix S1).
All efficacy analyses were performed on the ITT population. The primary, secondary and exploratory efficacy endpoints were analyzed overall and by CP class using descriptive statistics (Appendix S1).
Noncompartmental PK analyses were conducted, and all safety data were analyzed descriptively (Appendix S1).
Results from the primary analysis of the IMPACT study, when all patients had reached the SVR12 time point or had discontinued earlier, are presented. RAVs at baseline (Q80R in NS3 and Y93H in NS5A). In addition, 2 of 40 (5%) further patients had the daclatasvir RAV Y93H at baseline.
| RESULTS
| Patients
The S282T variant associated with resistance to sofosbuvir was not observed at baseline.
| Efficacy
All patients achieved SVR12 ( Figure 3A) . MELD scores decreased in 20 patients, were unchanged in 13 patients and increased in seven patients ( Figure 3B ).
| Pharmacokinetics
At week 8, the mean PK exposure (maximum plasma concentrations and area under the curve over the dosing interval [AUC 24h ]) to simeprevir, sofosbuvir, daclatasvir and GS-331007 was 2.2-, 1.5-, 1.2-and 1.2-fold higher in patients with CP B than in CP A, respectively, based on least-squares mean (LSM) ratios (Fig. S2) . Further PK data are presented in Appendix S1.
| Safety
During the treatment phase, there were no deaths or AEs that led to treatment discontinuation. Grade 1/2 AEs were reported in 26 of 40 (65%) patients. One patient in the CP B group had a Grade 3 AE during week 6 of treatment (gastrointestinal haemorrhage), which was also reported as a serious AE but was not considered related to the study drugs ( Table 2 ).
The most frequently reported AEs (in ≥2 patients) were pruritus, urinary tract infection, photosensitivity reaction, nausea, hepatic encephalopathy, anaemia, insomnia and irritability (Table 2) .
During the treatment phase of the study, 0 of 19 and 2 of 21 (10%) patients in the CP A and CP B groups, respectively, experienced clinical events related to hepatic decompensation (jaundice in one patient and gastrointestinal bleeding in another patient with previous history of an oesophageal bleed).
T [5%] patients, respectively), there were no concomitant increases in alanine aminotransferase/aspartate aminotransferase in either group.
Bilirubin increases were more frequent in the CP B group and correlated with higher plasma exposure of simeprevir; however, as previously reported, 20 these increases were isolated, well tolerated and did not lead to treatment discontinuation. in patients who received 12 weeks of treatment. 21 Notably, both of the currently recommended treatment combinations for HCV-infected patients with decompensated cirrhosis also include ribavirin.
| DISCUSSION
8,9
The combination of simeprevir and sofosbuvir for 12 weeks without ribavirin was assessed in two Phase III trials in treatment-naïve and (peginterferon±ribavirin) treatment-experienced HCV GT1-infected patients with (OPTIMIST-2) 16 or without (OPTIMIST-1) compensated
cirrhosis. 22 The regimen demonstrated superiority in SVR12 rates over historical control data in both studies. In the presence of cirrhosis in the OPTIMIST-2 study, numerically lower SVR12 rates were observed in HCV GT1a-infected patients with a baseline NS3 Q80K polymorphism compared with HCV GT1a-infected patients without this polymorphism (74% vs 92%). 16 In the current study, the presence of the NS3 Q80K polymorphism at baseline did not influence SVR12 rates,
suggesting that the addition of a third DAA to the simeprevir/sofosbuvir regimen was beneficial in overcoming the limitations of the dual combination when treating patients with cirrhosis.
The impact of SVR on the liver function of patients with advanced and decompensated liver disease is not well understood. Results from this study, in which all patients achieved SVR12, revealed improved or stabilized CP and MELD scores from baseline to follow-up week 12 in the majority of patients. The planned 5-year follow-up period will allow clinical changes to be monitored in these patients over an extended period of time and will provide further insight into the longterm benefits of achieving SVR in patients with advanced liver disease.
Of note, simeprevir, sofosbuvir, daclatasvir and GS-331007 exposures (AUC 24h ) were numerically higher in patients with CP B than CP A, consistent with the observation that decreased cytochrome P450 and drug transporter expression correlates with progression At least possibly related to sofosbuvir 1 (5) 5 (24) 6 (15) At least possibly related to daclatasvir 1 (5) 5 (24) 6 (15) AEs in ≥2 patients Pruritus 1 (5) 2 (10) 3 (8) Urinary tract infection 1 (5) 2 (10) 3 (8) Photosensitivity reaction 2 (11) 1 (5) 3 ( Overall, this three-DAA regimen was well tolerated. There were no discontinuations due to AEs, and only one on-treatment Grade 3 AE was reported and unrelated to the study drugs.
A major strength of this study is the inclusion of a 5-year follow-up period, which will be important in providing long-term outcomes in 
| CONCLUSION
The results from the ongoing IMPACT study indicate that the interferon-free, three-DAA combination of simeprevir, sofosbuvir and daclatasvir has the potential to become a short-duration, ribavirin-free and well-tolerated alternative regimen for the treatment of difficultto-cure, HCV GT1-infected patients. 
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